OSE Immunotherapeutics

Biotechnology ResearchFrance51-200 Employees

OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I).  
•	Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors.
•	Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL.
•	OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. 
•	FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis).
•	Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and  combo; Phase 2 in CRM diseases planned end 2024.
•	ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 

4 proprietary drug discovery platforms
•	Pro-resolutive mAb platform 
•	Myeloid Checkpoint platform 
•	BiCKI® Platform
•	mRNA Therapeutic platform f

Sign up for free to view info

Email Format Employee directory